安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Home - Mesoblast Ltd
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care
- Mesoblast Limited (MESO)
Find the latest Mesoblast Limited (MESO) stock quote, history, news and other vital information to help you with your stock trading and investing
- Mesoblast - Wikipedia
Mesoblast Limited is an Australian regenerative medicine company It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain The company is led by Silviu Itescu, who founded the company in 2004 [1]
- Mesoblast finally pushes GvHD cell therapy over finish line
Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children undergoing HSCT
- After two rejections, FDA approves Mesoblasts GVHD cell therapy
After two rejections from the FDA, Mesoblast has finally gained approval for its first drug, Ryoncil, a cell therapy for graft versus host disease
- Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval
Mesoblast snagged Food and Drug Administration approval for the first-ever treatment for children with a form of graft vs host disease The top-notch biotech stock rocketed Thursday
- Overview - Mesoblast Ltd
Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions
- FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
Mesoblast has gained US Food and Drug Administration (FDA) approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil (remestemcel-L), to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in paediatric patients aged a minimum of two months and up to adolescents and teenagers
|
|
|